Altimmune, Inc. with ticker code (ALT) now have 8 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 50 and 20 with a mean TP of 29.13. Given that the stocks previous close was at 14.03 this would imply there is a potential upside of 107.6%. The 50 day MA is 13.53 while the 200 day moving average is 11.76. The company has a market capitalisation of $660m. Company Website: https://altimmune.com
The potential market cap would be $1,371m based on the market concensus.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
